John Carreyrou
An investigative reporter for The Wall Street Journal, known for exposing fraud in Theranos's blood-testing technology; his reporting prompted an SEC investigation and the company's collapse.
Timeline (last 90 days)
In 2015, Wall Street Journal reporter John Carreyrou, based on leads provided by internal whistleblowers, investigated and exposed that Theranos devices fell far short of accuracy standards, with a large number of tests actually completed using third-party instruments.
Wall Street Journal reporter John Carreyrou's investigative reporting and his book Bad Blood are currently the most authoritative in-depth records of Theranos.
In 2015, an investigation by Wall Street Journal reporter John Carreyrou revealed that Theranos's core devices, Edison and miniLab, could not achieve the promised functionality.
A 2015 investigation by Wall Street Journal reporter John Carreyrou revealed that Theranos's core device could not perform the functions it had promised, and that the company was actually using conventional commercial blood analyzers to conduct tests.
John Carreyrou wrote the book "Bad Blood" about Theranos.
All Facts (5)
Wall Street Journal reporter John Carreyrou's investigative reporting and his book Bad Blood are currently the most authoritative in-depth records of Theranos.
50%UnverifiedIn 2015, an investigation by Wall Street Journal reporter John Carreyrou revealed that Theranos's core devices, Edison and miniLab, could not achieve the promised functionality.
50%UnverifiedJohn Carreyrou wrote the book "Bad Blood" about Theranos.
50%UnverifiedIn 2015, Wall Street Journal reporter John Carreyrou, based on leads provided by internal whistleblowers, investigated and exposed that Theranos devices fell far short of accuracy standards, with a large number of tests actually completed using third-party instruments.
50%UnverifiedA 2015 investigation by Wall Street Journal reporter John Carreyrou revealed that Theranos's core device could not perform the functions it had promised, and that the company was actually using conventional commercial blood analyzers to conduct tests.
50%